About CBL

With 30 years in the industry, CBL is recognized as a leader in peptide technology and manufacturing.  CBL’s business areas are GMP manufacturing of:  FMOC and BOC amino acids, solid phase resins, peptide intermediates, API and peptide generics.

CBL is committed to achieving the highest quality and regulatory standards.  This includes leading the  industry by utilizing GMPs for the manufacturing of  peptide starting materials.  Production of peptide clinical and commercial material is offered at all stages of the drug development process in facilities that allow for easy scale up from the early, smaller scale to commercial scale volumes.   To learn more about CBL and view the state-of-the-art, regulatory inspected facilities from FDA and EMA, visit us at www.cblpatras.gr.

  • GR
  • 2019
    On CPHI since
Contact info

Products from CBL (3)

  • Chlorotoxin

    Product Chlorotoxin

    Chlorotoxin is a 36-amino acid peptide found in the venom of the deathstalker scorpion (Leiurus quinquestriatus) which blocks small-conductance chloride channels. The fact that chlorotoxin binds preferentially to glioma cells has allowed the development of new methods for the treatment and diagnosis of severa...
  • Human Epidermal Growth Factor

    Product Human Epidermal Growth Factor

    Human EGF (hEGF) is consisting of 54 amino acids, is an identical molecule to β-urogastrone, a molecule isolated on the basis of its ability to inhibit gastric acid secretion. EGF is structurally homologous to human transforming growth factor-α, and both exert their actions through EGF receptors. This product...
  • Human Relaxin-2

    Product Human Relaxin-2

    Relaxin is a protein hormone of about 6000 Da first described in 1926 by Frederick Hisaw. The relaxin-like peptide family belongs in the insulin superfamily. This gene encodes multiple protein isoforms, at least one of which undergoes proteolytic processing. This processing generates relaxin A and B chains th...

CBL Resources (1)

  • News FDA & EMA inspected

    CBL, the “Peptide Innovators” was recently inspected both by the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA). Approvals were received from both agencies for the API manufacturing of octreotide.